This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2006 Feb 15;295(7):826-8.

doi: 10.1001/jama.295.7.826.

Obesity research--limitations of methods, measurements, and medications

Denise G Simons-Morton, Eva Obarzanek, Jeffrey A Cutler

PMID: 16478906
DOI: 10.1001/jama.295.7.826

Editorial

Obesity research--limitations of methods, measurements, and medications

Denise G Simons-Morton et al. JAMA. 2006.

. 2006 Feb 15;295(7):826-8.

doi: 10.1001/jama.295.7.826.

Authors

Denise G Simons-Morton, Eva Obarzanek, Jeffrey A Cutler

PMID: 16478906
DOI: 10.1001/jama.295.7.826

No abstract available

PubMed Disclaimer

Comment on

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial.
Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J; RIO-North America Study Group. Pi-Sunyer FX, et al. JAMA. 2006 Feb 15;295(7):761-75. doi: 10.1001/jama.295.7.761. JAMA. 2006. PMID: 16478899 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems